Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same
The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.
1. An anti-semaphorin 3A antibody comprising a heavy chain variable region containing CDR1 having an amino acid sequence shown in SEQ ID NO:68, CDR2 having an amino acid sequence shown in SEQ ID NO:69, and CDR3 having an amino acid sequence shown in SEQ ID NO:70, and a light chain variable region containing CDR1 having an amino acid sequence shown in SEQ ID NO:72, CDR2 having an amino acid sequence shown in SEQ ID NO:73, and CDR3 having an amino acid sequence shown in SEQ ID NO:74
or antibody fragment thereof containing an antigen binding region thereof.
2. The anti-semaphorin 3A antibody or antibody fragment thereof according to claim 1 , wherein the antibody or antibody fragment thereof is a chimeric antibody, a humanized antibody or an antibody fragment thereof.
3. A pharmaceutical composition comprising the anti-semaphorin 3A antibody or antibody fragment thereof according to claim 1 .
4. A method for treating Alzheimer's disease, comprising administrating the anti semaphorin 3A antibody or antibody fragment thereof according to claim 1 to a patient with Alzheimer's disease.
5. A method for measuring Sema 3A protein, comprising measuring Sema 3A protein in a sample using immunoassay with the anti-Sema 3A antibody or antibody fragment thereof according to claim 1 .
6. A kit for measuring Sema 3A protein, comprising the anti-Sema 3A antibody or antibody fragment thereof according to claim 1 .